Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644586 | 0.97 | LMNA (0.44) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL2231617 | 0.93 | HTT (0.41) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL1647371 | 0.93 | HTT (0.42) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL2230968 | 0.92 | SMN1; SMN2 (0.51) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL1647782 | 0.92 | LMNA (0.40) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL1647400 | 0.90 | SMN1; SMN2 (0.42) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL1646524 | 0.90 | LMNA (0.43) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL1646507 | 0.90 | LMNA (0.43) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL2231616 | 0.89 | SMN1; SMN2 (0.53) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL1644374 | 0.89 | LMNA (0.41) | LMNASMN1; SMN2HTTMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097413-B1 | 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2013-12-25 | — | — | EP | disclosed |
| US-8604029-B2 | 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD BRITISH BODY CORPORATE (GB) | 2013-12-10 | — | — | US | disclosed |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | disclosed |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD. | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | IDO1, FOXM1, IPO5 | LMNA 3870/4885SMN1; SMN2 3682/4885HTT 1809/4885 |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | NAT1, AGXT, CYP1A2 | LMNA 1805/4885SMN1; SMN2 3079/4885HTT 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.